Martínez S and Tornador C
Alterations in the MET proto-oncogene, such as amplification or mutations causing exon 14 skipping, promote tumor growth, cellular transformation and invasion and are associated with poor prognosis in many types of cancers. There are several c-Met-targeted agents currently in clinical trials, highlighting the importance on developing accurate, efficient and sensitive technologies for the analysis. This short communication will provide an update on three of the most useful technologies for the detection of c-Met exon 14 skipping abnormalities, namely New Generation Sequencing (NGS), nCounter and qPCR.
Compartilhe este artigo